All News

RA,polyarticular,black,rheumatoid

ALTO: Long-Term Abatacept Outcomes in At-Risk RA

Jack Cush, MD

Lancet Rheumatology has published the ALTO results - long term outcomes of the APIPPRA trial, demonstrating that treatment with abatacept (ABA) in at risk patients can delay progression to rheumatoid arthritis (RA) for up to 4 years.

Read Article
artangiogca.jpg

Giant Cell Arteritis Outcomes in Canada

Jack Cush, MD

A retrospective cohort study of patients with giant cell arteritis (GCA) demonstrates relapses are common and seen in nearly half of patients, were common after treatment is stopped and is not effectively averted by methotrexate (MTX).

Read Article
Pain,FM,fibromlyalgia,Trigger

Which Fibromyalgia Drugs are Cost-Effective?

Jack Cush, MD

A cost-effectiveness analysis compared FDA approved fibromyalgia drugs (pregabalin, duloxetine, milnacipran) with amitriptyline and found duloxetine was the preferred strategy across perspectives.

Read Article
research2.jpg

Canada's 2025 Top 10 Funded Rheumatology Projects

Arthritis Society

Arthritis Society Canada (ASC) is Canada’s largest charitable funder of cutting-edge arthritis research, investing more than $240 million in research projects since its founding, and over $7 million invested in 2024-2025. Below are the investigators and projects that were funded in 2025.

Read Article
MTX.box

Methotrexate intolerance in rheumatoid arthritis

Jack Cush, MD

A current large rheumatoid arthritis (RA) cohort study from Cairo assessed methotrexate (MTX) use and found over half were MTX intolerant and a third of patients were noncompliant with MTX.

Read Article
The challenge may be that lupus has multiple endotypes with variable rates of progression/trajectories. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/BA4KRKebIv
Dr. John Cush RheumNow ( View Tweet)
Study of 286 RA pt finds comorbidity burden—particularly psychological comorbidity—was strongly associated with poorer HRQoL and greater management difficulty in RA. https://t.co/F90S55DaI6 https://t.co/4Hw1yTUgP5

Links:

Dr. John Cush RheumNow ( View Tweet)
RA outcomes according to onset: typica RA vs undifferentiated inflam arthritis (UIA) or palindromic rheumatism (PR). Progress to RA = RA > UIA > PR. PR has more +FHx & ACPA; UIA more females w/ Knee Sxs. Best remission rates w/ PR onsets. https://t.co/JJRCdKcs1u https://t.co/n385f6EF59

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate intolerance in rheumatoid arthritis A current large rheumatoid arthritis (RA) cohort study from Cairo assessed methotrexate (MTX) use and found over half were MTX intolerant and a third of patients were noncompliant with MTX. https://t.co/PDUv2YRFIq https://t.co/2DuBXjNqec

Links:

Dr. John Cush RheumNow ( View Tweet)
Long term outcomes study of 22 pts w/ adult Stills. 16 (72.7%) completed LTE w/ mean observation 168.9 wks. 3/22 had serious adverse events, Tx efficacy ACR70=68% and 95% reduced in glucocorticoid doses w/ 41% in GC-free remission https://t.co/h0MvDLWGhD https://t.co/HDIKF7VMwA

Links:

Dr. John Cush RheumNow ( View Tweet)
2016 ARTIC trial tested T2T w/ MTX & "bridging" tapered Prednisolone (15 mg --> 0mg over 7wks) in 237 new DMARD naive RA pts. PRED discontinuation successful in 84% @7wks, 89% @3mos, 95% @ 24 mos. Only 5% require Pred @ every visit for 2 yrs. You can D/C pred! https://t.co/O23PHq81YP
Dr. John Cush RheumNow ( View Tweet)
Retractions in Rheumatology Retractions in rheumatology are rising. An analysis of Retraction Watch data found 381 retracted articles (1989–2024), driven by misconduct or data errors. 68.5% originated in Asia, over half from China (50.7%). https://t.co/I6WmceNi2m https://t.co/6z0jHPaiaR

Links:

Dr. John Cush RheumNow ( View Tweet)
Notch and TGFβ Signaling in Refractory Rheumatoid Arthritis Spatial transcriptomic profiling of rheumatoid arthritis (RA) synovial biopsies (pre- and post-treatment) has revealed new insights into the pathobiology or treatment resistent RA. https://t.co/vCvFpnIOvS https://t.co/EV6OihT0br

Links:

Dr. John Cush RheumNow ( View Tweet)
TOPKAT Trial: Partial vs Total Knee Replacement Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit https://t.co/SsTXAqs4Xr
Dr. John Cush RheumNow ( View Tweet)
TOPKAT Trial: Partial vs Total Knee Replacement Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit https://t.co/MNpVeHQbJ2
Dr. John Cush RheumNow ( View Tweet)
Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/IEC0tsp1Rk https://t.co/jIsqhy9rQh

Links:

Dr. John Cush RheumNow ( View Tweet)
APPIPRA Study - Benefits of Early Treatment Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped. https://t.co/GYguq7VlqT https://t.co/5Z0BXIm3cM

Links:

Dr. John Cush RheumNow ( View Tweet)
Remission? Single center study of 100 RA, 100 SLE pts assessed by SLEDAI-2K, SDAI, VAS. Remission/LDA found in 88% of 392 SLE visits & 91% of 389 RA visits(p=NS). Remission was more common in SLE vs RA (79% vs 69%; p= 0.0018). https://t.co/ZPRrYQMsCT

Links:

Dr. John Cush RheumNow ( View Tweet)

Physical activity (PA) is assoc w/ reduced all-cause mortality in RA pts. Study of 1493 NHANES & 1724 UK Biobank RA cohorts showing robust inverse association between PA and all-cause mortality (HR: active = 0.48, highly active = 0.61) https://t.co/K6ALzqP3QQ https://t.co/2XJ0zD7FA3

Links:

Dr. John Cush RheumNow ( View Tweet)
Electronic EHR reminders to deprescribe works! EHR study of 1146 pts(mean 74 yrs) showed 2 methods of E-reminder notifications resulted in either a 10.4% or 6.5% deprescribing (vs usual care); deprescribing was 40% more likely (RR 1.40; 95% CI, 1.14-1.73) https://t.co/sXnW5gUP0q https://t.co/n9LhUG612M

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×